Newron Declines 12% in Zurich Trading as Talks Over Sale to Santhera End

Newron Pharmaceuticals SpA, the Italian drugmaker developing a Parkinson’s disease treatment with Merck KGaA, fell in Zurich trading after saying talks with Santhera Pharmaceuticals Holding AG have ended.

The stock fell 80 centimes, or 12 percent, to 5.90 Swiss francs at 9:05 a.m.

To contact the editor responsible for this story: Phil Serafino at

Bloomberg reserves the right to edit or remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.